Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 02, 2015 4:37 PM ET

Pharmaceuticals

Company Overview of Tris Pharma, Inc.

Company Overview

Tris Pharma, Inc., a specialty pharmaceutical company, researches, develops, manufactures, and markets over-the-counter, Rx branded, and specialty generic products in the United States. The company develops extended release formulations for products intended for children, seniors, and adults who have difficulty swallowing pills and require multi-dose treatment. It also offers OralXR+, a particulate-based technology in which millions of small particles deliver the drug over time; Nobuse, an abuse resistant proprietary technology; and specialty generic products in immediate and extended release versions. In addition, it offers Lipisol for lipophilic/insoluble drugs (log P 1 to 5) as liquid-fil...

2033 Route 130

Brunswick Business Park

Suite D

Monmouth Junction, NJ 08852

United States

Founded in 2000

Phone:

732-940-2800

Fax:

732-940-2855

Key Executives for Tris Pharma, Inc.

Founder, Chief Executive Officer and President
Vice President of Operations & Technical Services
President of Generic Pharmaceuticals Business
Age: 51
Chief Medical Officer
Vice President of Human Resources
Compensation as of Fiscal Year 2015.

Tris Pharma, Inc. Key Developments

Tris Pharma, Inc. Enters into License, Supply, and Distribution Agreement with Pfizer Consumer Healthcare

Tris Pharma, Inc. announced that it has entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare. Under the terms of the agreement, Pfizer Consumer Healthcare will commercialize Tris' extended release dextromethorphan cough syrup under the Robitussin Brand. In exchange for providing Pfizer Consumer Healthcare U.S. branded rights to its protected intellectual property for an extended release dextromethorphan formulation, Tris will receive an upfront payment, milestone payments and sales-based royalties. Tris will be responsible for manufacturing and regulatory activities while Pfizer Consumer Healthcare will manage sales, marketing, and distribution.

Tris Pharma, Inc. Manufactures 3 Registration Batches of CCP-07

Vernalis plc announced that its partner, Tris Pharma, has successfully manufactured 3 registration batches of CCP-07 and material from these batches is now up on stability. CCP-07 is the second programme in Vernalis' cough cold pipeline from its exclusive licensing agreement with Tris Pharma. The first product, Tuzistra XR was approved by the FDA on 30 April 2015. The CCP-07 NDA submission will include 12 months of stability data and so Tris now anticipates the filing with the FDA to occur during 2016. Further news flow will follow the completion of the pivotal single-dose and multi-dose bioavailability studies anticipated to take place between now and NDA filing. Tris is developing, on behalf of Vernalis, up to six unique extended-release equivalents to existing immediate-release prescription cough cold treatments. The financial terms of this licensing deal are not disclosed.

Tris Pharma, Inc. Announces the FDA Acceptance of NDA for Dyanavel™ XR

Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension. The FDA has set a Prescription Drug User Fee Act (PDUFA) target date for mid-October, 2015. Dyanavel XR was developed using Tris' innovative technology, LiquiXR®, which has already produced several breakthrough products. The NDA submission was based on a multicenter, phase III efficacy study conducted in over 100 patients, which demonstrated a positive outcome by meeting all its primary end points.

Similar Private Companies By Industry

Company Name Region
PolyMedica Pharmaceuticals (U.S.A.), Inc. United States
BioMedomics, Inc. United States
BioPharma Management Technologies, Inc. United States
BattelleCRO, Inc. United States
Acetylon Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tris Pharma, Inc., please visit www.trispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.